

	2014												2013
	Q1(1)			Q2(1)(2)			Q3(1)(3)			Q4(1)(4)			Q1(5)			Q2(5)			Q3(5)		Q4(6)
	(In thousands, except per share amounts)
Net sales	$	39,614		$	43,555		$	58,786		$	62,959		$	37,675		$	39,453		$	39,763	$	41,920
Gross profit	29,280			33,049			43,086			46,040			27,356			28,828			29,710		31,561
Net (loss) income	(5,661		)	(5,299		)	(13,944		)	(15,997		)	(959		)	(728		)	434		883
Net (loss) income per share (7):
Basic	$	(0.14	)	$	(0.13	)	$	(0.33	)	$	(0.38	)	$	(0.03	)	$	(0.02	)	$	0.01	$	0.02
Diluted	$	(0.14	)	$	(0.13	)	$	(0.33	)	$	(0.38	)	$	(0.03	)	$	(0.02	)	$	0.01	$	0.02


(1)	During the first, second, third and fourth quarters of 2014, the Company incurred $0.3 million, $4.0 million, $3.8 million and $7.8 million, respectively, in transaction and integration costs related to the acquisition of AngioScore. See Note 2, “Business Combinations.”

(2)

Net loss and net loss per share have been adjusted from the previously filed Form 10-Q as of June 30, 2014 to reflect adjustments made during the measurement period to provisional amounts recognized for the AngioScore acquisition at the acquisition date. The Company recorded a deferred tax benefit of $1.3 million related to a partial release of valuation allowance related to the AngioScore acquisition. See Note 14, “Income Taxes.”


(3)	During the third quarter of 2014, the Company recorded an impairment charge of $4.1 million and a reduction of $1.1 million to the contingent consideration liability related to certain assets and liabilities recorded from the acquisition of Upstream in 2013. See Note 6, “Goodwill and Other Intangible Assets.”


(4)	During the fourth quarter of 2014, the Company incurred $1.5 million in transaction costs related to the acquisition of the Stellarex DCB Assets. See Note 17, “Subsequent Event.”


(5)	During each of the first, second and third quarters of 2013, the Company incurred $0.5 million of medical device excise tax (which commenced January 1, 2013), $0.2 million in contingent consideration expense, and $0.2 million in acquisition-related intangible asset amortization, respectively.

(6)

During the fourth quarter of 2013, the Company incurred $0.6 million of medical device excise tax expense, $0.2 million in contingent consideration expense, and $0.2 million in acquisition-related intangible asset amortization. In addition, during the fourth quarter of 2013, the Company recorded an intangible asset impairment of $4.5 million and an adjustment to the contingent consideration liability of $5.2 million related to certain assets and liabilities recorded from the acquisition of Upstream in 2013. See Note 6, “Goodwill and Other Intangible Assets.”


(7)	The sum of the quarterly net income per share amounts may not total to each full year amount because these computations are made independently for each quarter and for the full year, and take into account the weighted average number of common stock equivalent shares outstanding for each period.